Kolexia
Houede Nadine Oncologie médicale
Houede Nadine
Oncologie médicale
Hôpital Carémeau
Nîmes, France
281 Activités
48 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la prostate Tumeurs de la vessie urinaire Carcinomes Tumeurs prostatiques résistantes à la castration Métastase tumorale Carcinome transitionnel Récidive tumorale locale Tumeurs du rein Néphrocarcinome

Collaborateurs

Voir plus
Roupret Morgan
Roupret Morgan
Hôpital Pitie Salpetriere, Paris, France
Neuzillet Yann
Neuzillet Yann
Hôpital Foch, Suresnes, France
Pignot Geraldine
Pignot Geraldine
Centre Paoli-Calmettes, Marseille, France
Oudard Stephane
Oudard Stephane
Hôpital Européen Georges Pompidou, Paris, France

Industries

Voir plus
CanceroDigest
49 collaboration(s)
Dernière en 2023
Janssen
24 collaboration(s)
Dernière en 2023
Ipsen
24 collaboration(s)
Dernière en 2023
Astellas
19 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
THOR: A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations
Essai Clinique (Janssen)   27 février 2024
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley): A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Essai Clinique (Emd Serono)   05 février 2024
QUALIOR: Study Evaluating the Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program, for Metastatic Cancer Patients Receiving Oral Targeted Therapy: The UNICANCER SdS 01 QUALIOR Study
Essai Clinique (Unicancer)   07 novembre 2023
Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.
JAMA oncology   26 octobre 2023
Les études de la plateforme THOR évaluant l’erdafitinib dans le cancer de la vessie
Edimark   21 octobre 2023
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
The New England journal of medicine   21 octobre 2023
IREKI: Study of the Impact of the Stage of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors (ITK) in Patients Treated for Metastatic Kidney Cancer
Essai Clinique (Institut du Cancer de Montpellier)   19 octobre 2023
Nadine... - Sociéte des Membres de la Légion d'Honneur du Gard
Facebook   06 octobre 2023
2362MO Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
1808P Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel every 2 weeks (16 mg/m2) versus every 3 weeks (25 mg/m2) in the CABASTY phase III trial
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023